How can molecular abnormalities influence our clinical approach.

about

How can molecular abnormalities influence our clinical approach.

Item

http://www.wikidata.org/entity/Q49896005

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

How can molecular abnormalities influence our clinical approach.

@en

How can molecular abnormalities influence our clinical approach.

@nl

type

Item

label

How can molecular abnormalities influence our clinical approach.

@en

How can molecular abnormalities influence our clinical approach.

@nl

prefLabel

How can molecular abnormalities influence our clinical approach.

@en

How can molecular abnormalities influence our clinical approach.

@nl

P1476

How can molecular abnormalities influence our clinical approach

@en

P2093

B Wu

http://www.w3.org/2001/XMLSchema#string

F Giulia

http://www.w3.org/2001/XMLSchema#string

M J Birrer

http://www.w3.org/2001/XMLSchema#string

M Tavallai

http://www.w3.org/2001/XMLSchema#string

R T Bekele

http://www.w3.org/2001/XMLSchema#string

S Luffer

http://www.w3.org/2001/XMLSchema#string

W Wei

http://www.w3.org/2001/XMLSchema#string

P2860

Ovarian carcinoma subtypes are different diseases: implications for biomarker studies

ARID1A mutations in endometriosis-associated ovarian carcinomas

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.

Integrated genomic analyses of ovarian carcinoma

Germline mutations in RAD51D confer susceptibility to ovarian cancer

Mutations in BRIP1 confer high risk of ovarian cancer

Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma

Ultra-deep sequencing detects ovarian cancer cells in peritoneal fluid and reveals somatic TP53 mutations in noncancerous tissues

Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis

Identification of novel therapeutic targets in microdissected clear cell ovarian cancers

P304

viii16-viii24

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1093/ANNONC/MDX447

http://www.w3.org/2001/XMLSchema#string

P433

suppl_8

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Rajesh Kumar

P577

2017-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29232470

http://www.w3.org/2001/XMLSchema#string